vision loss with tirzepatide does affect GLP-1s and Eye Health: What You Need to Know Eye Complications Found With Use
Description
tirzepatide patent cliff in the early-to-mid 2030s
This comprehensive strategy has the potential to improve not only glycemic control but also overall cardiovascular health, as excessive weight and high blood sugar are risk factors for heart disease

Mild nausea, digestive changes, or fatigue are possible with Tirzepatide

More Powerful Glycemic Control Both tirzepatide and retatrutide significantly improve blood sugar control
SURMOUNT-1 (Obesity without T2D) The SURMOUNT-1 trial was a landmark study that enrolled 2,539 participants with obesity or overweight (but without T2D) and at least one weight-related comorbidity
Mazdutide was approved by Chinas NMPA for chronic weight management in 2025, and GLORY-1 showed clinically relevant weight loss in Chinese adults with overweight/obesity